

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

china.com

China.com Inc.

中華網科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8006)

CONNECTED TRANSACTION

PURCHASE OF 751,550 SHARES OF CDC STOCK

The Board of Directors of China.com Inc. (the “Company”) announces that the Company purchased an aggregate of 751,550 shares of CDC Stock (the “Purchases”) on the NASDAQ Global Market between September 13, 2007 and December 18, 2007, for aggregate consideration of US\$4,885,668 (equivalent to approximately HK\$38,108,210).

Mr. Yip Hak Yung Peter is director and chief executive of the Company. Mr. Yip (together with his associates) is also a substantial shareholder of CDC. Therefore, the Purchases of CDC Stock constitute a connected transaction under Rule 20.13(1)(b)(i) of the GEM Listing Rules. As all relevant percentage ratios of this transaction are less than 2.5%, this transaction is exempt from the independent shareholders’ approval requirement under Rule 20.32 of the GEM Listing Rules, but is still subject to the reporting and announcement requirements under Rule 20.45 to 20.47 of the GEM Listing Rules.

STOCK BUYING PROGRAM

Date

The Company entered into the Rule 10b5-1 Plan with GunnAllen as of September 20, 2007, and purchased 366,000 shares of CDC Stock thereunder. The maximum number of shares of CDC Stock that the Company agreed to purchase, as contemplated by the Rule 10b5-1 Plan was 366,000 shares of CDC Stock.

Depending on timing and other factors, the Company may make purchases of CDC Stock either with or without a Rule 10b5-1 Purchase Plan in place. A benefit of establishing a Rule 10b5-1 Purchase Plan, however, is that it provides the Company with affirmative defenses to alleged violation of Rule 10b5-1 (insider trading) under

the U.S. Securities Laws. Since Rule 10b5-1 Purchase Plans (which include purchase or sale instructions, price targets, volume limitations and other criteria) must be established when the Company is not in receipt of material non-public information, the transactions thereunder are, subject to certain conditions, non-discretionary. As a result, the Company can continue (through a third party) to transact open-market purchases and sales under the pre-determined criteria even though it may subsequently become aware of material non-public information, at which time transactions without having a Rule 10b5-1 Purchase Plan in place would be prohibited.

The Company is restricted from subsequent sale of CDC Stock when it is aware of the material nonpublic information of CDC Corporation or any of its subsidiaries or affiliates.

Furthermore, there are additional restrictions on subsequent sales of CDC Stock. CDC owns approximately 77% of the Company's issued ordinary shares. The Company is an affiliate of CDC under applicable U.S. securities laws. Once shares of CDC Stock are acquired by the Company under a Rule 10b5-1 Plan, the securities will become "control shares".

Control shares are subject to the following limitations and restrictions:

- (i) There must be adequate current information about the issuer of the securities (CDC) before sales of the CDC Stock could be made by the Company. This generally means that CDC must have complied with the periodic reporting requirements of the Securities Exchange Act of 1934.
- (ii) The number of shares of CDC Stock that the Company may sell during any three-month period must not exceed the greater of 1% or the average reported weekly trading volume during the four weeks preceding the filing a notice of the sale on Form 144.
- (iii) Sales of CDC Stock by the Company must be handled in all respects as routine trading transactions, and brokers may not receive more than a normal commission.
- (iv) At the time the Company places its order to sell CDC Stock, the Company must file a notice with the SEC on Form 144 if the sale involves more than 5,000 shares or the aggregate dollar amount is greater than US\$50,000 in any three-month period. The sale must take place within three months of filing the Form and, if the securities have not been sold, the Company must file an amended notice.

Additionally, CDC must maintain an effective registration statement on file with the SEC.

Parties

The parties to both the Rule 10b5-1 Plan are the Company, which is established under the laws of the Cayman Islands with limited liability, and whose shares are listed on the GEM (Stock Code: 8006), and GunnAllen, a brokerage and investment banking firm conducting business in the State of Florida. The Company confirms that, in accordance with GEM Rule 19.58(4), to the best of its directors' knowledge, information and belief having made all reasonable enquiry, GunnAllen and its ultimate beneficial owners are third parties independent of the Company and its connected persons. CDC Stock is traded on the NASDAQ Global Market. GunnAllen is a FINRA registered securities broker-dealer. Since all the Purchases were made on the open market, the Company does not know the identities of the sellers of the CDC Stock. However, the Company does not have any evidence that the sellers are connected persons of the Company.

Value of Transaction

Up to the date hereof, the Company has purchased 751,550 shares of CDC Stock, or approximately 0.7% of all outstanding CDC Stock, for an aggregate amount of approximately US\$4,885,668 (equivalent to approximately HK\$38,108,210). Out of those 751,550 shares, 366,000 shares were purchased under the Rule 10b5-1 Plan. All Purchases were made on the open market at market price. A breakdown of the Previous Purchases is set out below:

Date of Purchase	Volume <i>(Shares)</i>	Price <i>(US\$ per share)</i>
9/13/07	170,200	7.3098
9/14/07	76,800	7.1309
9/18/07	21,000	7.1057
9/20/07	57,550	6.9170
11/6/07	25,000	6.9536
11/7/07	25,000	6.8472
11/8/07	25,000	6.5638
11/8/07	50,000	6.3434
11/9/07	50,000	6.2209
11/12/07	100,000	5.9738
11/13/07	50,000	6.1667
11/14/07	41,000	6.4927
12/18/07	60,000	3.9558

The closing price of CDC Stock on February 29, 2008 was US\$3.81 per share, and the market value of the 751,550 shares of CDC Stock as at such date was US\$2,863,400 (equivalent to approximately HK\$22,334,560).

CDC Corporation did not declare any dividends in the last two financial years. Therefore, the net profits attributable to the CDC Stock purchased or to be purchased was nil for the last two financial years.

Certain key financial information about CDC for the last two financial years is set out below for reference:

	Year ended Dec. 31, 2005	Year ended Dec. 31, 2006
Net profits before tax and extraordinary items	US\$2,902,000	US\$16,214,000
Net profits after tax and extraordinary items	(US\$3,464,000)	US\$10,840,000
Net asset value	US\$446,498,000	US\$454,623,000
Net profits per share before tax and extraordinary items	US\$0.03	US\$0.15
Net profits per share after tax and extraordinary items	(US\$0.03)	US\$0.10
Net asset value per share	US\$4.02	US\$4.17

Consideration and Payment Terms

The price, daily volume and cumulative volume limits under the Rule 10b5-1 Plan were:

Price Limit <i>(US\$ per share)</i>	Daily Volume Limit <i>(Shares)</i>	Cumulative Volume Limit <i>(Shares)</i>
\$6.00 or below	100,000	None
\$6.50 or below	50,000	None
\$7.00 or below	25,000	None
Total	175,000	366,000

In determining the bid price for purchases made between September 13, 2007 and September 20, 2007 and on December 18, 2007 and the price limits for the Rule 10b5-1 Plan, the Company considered the following factors:

- (i) the publicly-available financial information of CDC;
- (ii) recommendations contained in publicly-available reports from independent, professional financial analysts; and
- (iii) the historical price performance of the CDC Stock.

Since the relevant bid prices for the purchases made between September 13, 2007 and September 20, 2007 and on December 18, 2007, and the price limits set by the Company in the Rule 10b5-1 Plan, were below the target prices for CDC Stock set by financial analysts at the relevant times, the Company believed that they were fair and reasonable. Furthermore, the Company believes that the true value underlying CDC Stock is based on potential price appreciation and not CDC's payment, or non-payment, of dividends.

The analyst reports reviewed and considered by the Company included but not limited to those:

- (a) written by Andrey Glukhov, CFA and Michael Tieu, CFA of Brean Murray Carret & Co. and issued on September 6, 2007;
- (b) written by J. Derrick Wood, CFA and Frank Law of Pacific Growth Equities and issued on September 7, 2007;
- (c) written by Steven Freitas of BMO Capital Markets Corp. and issued on September 7, 2007;
- (d) written by Mark Verbeck of Cantor Fitzgerald and issued on December 14, 2007; and
- (e) written by Michael Huang, Atul Bagga, Darren Aftahi and Traci Mangini of ThinkEquity Partners LLC and issued on December 17, 2007.

The Company paid GunnAllen a commission at the rate of US\$0.03 per share. This commission rate is the result of a negotiation between the Company and GunnAllen. Brokerage companies in the United States typically charge a commission at the rate of US\$0.02 to US\$0.04 per share for similar transactions. The Company believes that the commission rate of US\$0.03 per share offered by GunnAllen is fair and reasonable.

BUSINESS OF THE PARTIES

The Company is currently principally engaged in the operation of a broad range of content value-added community services and e-commerce capabilities through online, offline and wireless media in principally the PRC and also Hong Kong and Singapore, comprising operations of mobile value added services, Internet portal, and trade publication and events.

CDC is a global provider of enterprise software, mobile services and applications, internet and media services and the development and operation of online games principally in the People's Republic of China, North America, Europe and Australia. CDC has not declared any dividends within the past two years.

GunnAllen is principally engaged in brokerage and investment banking.

REASONS FOR THE TRANSACTION

The Company has approximately HK\$1.2 billion in net cash balances and available-for-sale investments, and is exploring investment opportunities to optimize its portfolio by enhancing yield and maximizing shareholders' value. Having reviewed and considered recommendations contained in publicly-available reports from independent, professional financial analysts on CDC, the Executive Committee of the Board of Directors of

the Company believed that CDC Stock was currently significantly undervalued. The Executive Committee of the Board (including an independent non-executive director) was of the view that the purchase of CDC Stock was on normal commercial terms, fair and reasonable so far as the Company and the Shareholders as a whole are concerned, and was in the best interest of the Company.

The Company has determined that the investment in CDC Stock will be booked as listed securities on the Company's balance sheet. The Company intends to hold the CDC Stock as non-current available-for-sale investment.

GEM LISTING RULES IMPLICATIONS

Mr. Yip Hak Yung Peter is director and chief executive of the Company. Mr. Yip (together with his associates) is also a substantial shareholder of CDC. Therefore, the Purchases of CDC Stock constitute a connected transaction under Rule 20.13(1)(b) (i) of the GEM Listing Rules. As all relevant percentage ratios of this transaction are less than 2.5%, this transaction is exempt from the independent shareholders' approval requirement under Rule 20.32 of the GEM Listing Rules, but is still subject to the reporting and announcement requirements under Rule 20.45 to 20.47 of the GEM Listing Rules.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the following meanings:

“\$” or “US\$”	means the U.S. dollar, the legal currency of the U.S.
“CDC Corporation” or “CDC”	means CDC Corporation, a company established under the laws of the Cayman Islands with limited liability, whose shares are listed on the NASDAQ Stock Market (CHINA). CDC Corporation is the ultimate holding company of China.com.
“CDC Stock”	means Class A common shares of CDC Corporation of par value US\$0.00025 each.
“Company” or “China.com”	means China.com Inc., a company established under the laws of the Cayman Islands with limited liability, whose shares are listed on GEM of The Stock Exchange of Hong Kong Limited (Stock Code: 8006). References to the Company shall be construed as China.com Inc. and its subsidiaries, as applicable.

“Executive Committee of the Board”	means the executive committee of the board of directors of China.com Inc.
“FINRA”	means The Financial Industry Regulatory Authority, a non-governmental regulator for all securities firms doing business in the United States.
“GEM”	means the Growth Enterprise Market of the Stock Exchange.
“GEM Listing Rules”	means The Rules Governing the Listing of Securities on GEM.
“GunnAllen”	means GunnAllen Financial Incorporated, a brokerage and investment banking conducting business in the State of Florida.
“Rule 10b5-1 Plan”	means the Rule 10b5-1 Purchase Plan entered into between the Company and GunnAllen as of September 21, 2007.
“Rule 10b5-1”	means Rule 10b5-1 under the Securities Exchange Act of 1934 of the United States.
“Rule 10b5-1 Purchase Plan”	means, generally, a stock buying program made pursuant to the requirements of and in conformity with the provisions of Rule 10b5-1 under the Securities Exchange Act of 1934 of the United States.
“SEC”	means the Securities and Exchange Commission of the United States.
“Shareholders”	means the shareholders of the Company.
“Stock Exchange”	means the Stock Exchange of Hong Kong Limited.

On behalf of the Board
China.com Inc.
Yip Hak Yung, Peter
Executive Director

Hong Kong, March 6, 2008

As at the date of this announcement, the executive directors of the Company are Mr. Yip Hak Yung, Peter, Dr. Cheng Loi, the non-executive directors are Dr. Ch'ien Kuo Fung, Raymond, Mr. Fang Xin and the independent non-executive directors are Mr. Wong Sin Just, Mr. Wang Cheung Yue, Fred, Mr. Chia Kok Onn, Dr. Lam Lee G and Mr. Anson Wang.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are found on bases and assumptions that are fair and reasonable.

This announcement will remain on the GEM website at www.hkgem.com on the latest Company Announcements page for at least 7 days from the date of its posting and on the website of the Company at www.inc.china.com.